Bullish for Gujarat Themis Biosyn: Strong Bulk Drug Growth Momentum

Gujarat Themis Biosyn Ltd (GTBL) is highlighted for its strong growth momentum in bulk drugs. The company, incorporated in 1981, is now owned by the Yuhan Group (South Korea) and actively managed by Themis Medicare Ltd (THEMISMED).

This indicates a robust business model within the pharmaceutical sector, driven by specialized bulk drug manufacturing and backed by strong international and domestic pharmaceutical players. The active management by THEMISMED suggests strategic alignment and potential for sustained growth.

GTBL, despite its smaller market cap, could see increased investor interest due to its growth prospects in bulk drugs. THEMISMED, as the active manager, might also benefit from GTBL's success, potentially leading to positive sentiment for both entities.

Traders should monitor GTBL's quarterly results for continued growth in bulk drug sales and profitability. Also, keep an eye on any announcements regarding expansion plans or new product developments, which could further fuel its growth trajectory.

• •Gujarat Themis Biosyn Ltd (GTBL) shows 'Bulk Drugs growth momentum'.
• •GTBL was incorporated in 1981 and commenced production in 1985.
• •Taken over in 1991 by the Yuhan Group (South Korean pharma) and Pharmaceutical Business Group (India) Ltd.
• •Actively managed by Themis Medicare Ltd (JV Company of Gedeon Richter Ltd, Hungary) since 2007.
• •Current Market Cap: 290.21 Cr, Current Price: 199.75, P/E: 12.26.